QLIF-12. HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1p/19q INTACT FIRS RECURRENCE WHO GRADE II AND III GLIOMA (EORTC 26091)

摘要

BACKGROUNDIn an international randomized controlled phase II study of temozolomide (TMZ) vs TMZ in combination with Bevacizumab (BEV) in locally diagnosed non-1p/19q co-deleted grade II or III glioma with a first and contrast-enhancing recurrence after initial radiotherapy, overall survival at 12 months (OS12) was not significantly different (61% in the TMZ arm and 55% in the TMZ+BEV arm).